Journal of Jilin University(Medicine Edition) ›› 2023, Vol. 49 ›› Issue (3): 802-810.doi: 10.13481/j.1671-587X.20230333
• Review • Previous Articles Next Articles
Research progress in mechanism and treatment strategy of hypertrophic obstructive cardiomyopathy patients complicated with mitral insufficiency
-
Received:2022-08-22Online:2023-05-28Published:2023-06-28
CLC Number:
- R542.2
Cite this article
share this article
Fig. 1
Schematic diagram of pushing force of blood flow on mitral valve leaflet"
Fig. 1
Fig. 2
Expansion of anterior mitral valve leaflet"
Fig. 2
Fig. 3
Resection-Plication-Release repair"
Fig. 3
Fig. 4
Anterior mitral leaflet retention plasty"
Fig. 4
Fig. 5
Floating stitch technique"
Fig. 5
| 1 | ROBERTS R， SIGWART U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy［J］.Circulation， 2005，112（2）： 293-296. |
| 2 | MARON M S， OLIVOTTO I， ZENOVICH A G，et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction［J］. Circulation， 2006， 114（21）： 2232-2239. |
| 3 | BRAUNWALD E. Obstruction in hypertrophic cardiomyopathy： how often does it occur？ Should it be treated？ If so， how？［J］. Circulation， 2012， 126（20）： 2369-2370. |
| 4 | CARDIM N， GALDERISI M， EDVARDSEN T，et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy： an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association［J］. Eur Heart J Cardiovasc Imaging， 2015， 16（3）： 280. |
| 5 | ANTUNES M O， SCUDELER T L. Hypertrophic cardiomyopathy［J］. Int J Cardiol Heart Vasc， 2020， 27： 100503. |
| 6 | YU E H， OMRAN A S， WIGLE E D， et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy： relationship to obstruction and relief with myectomy［J］. J Am Coll Cardiol， 2000， 36（7）： 2219-2225. |
| 7 | HENRY W L， CLARK C E， GRIFFITH J M， et al. Mechanism of left ventricular outlfow obstruction in patients with obstructive asymmetric septal hypertrophy （idiopathic hypertrophic subaortic stenosis）［J］. Am J Cardiol， 1975， 35（3）： 337-345. |
| 8 | DELLING F N， SANBORN D Y， LEVINE R A，et al. Frequency and mechanism of persistent systolic anterior motion and mitral regurgitation after septal ablation in obstructive hypertrophic cardiomyopathy［J］. Am J Cardiol， 2007， 100（11）： 1691-1695. |
| 9 | RO R， HALPERN D， SAHN D J， et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve［J］. J Am Coll Cardiol， 2014， 64（19）： 1984-1995. |
| 10 | SHERRID M V， GUNSBURG D Z， MOLDENHAUER S， et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy［J］. J Am Coll Cardiol， 2000， 36（4）： 1344-1354. |
| 11 | SILBIGER J J. Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy： echocardiographic， pathophysiologic， and surgical insights［J］. J Am Soc Echocardiogr， 2016， 29（7）： 622-639. |
| 12 | TEO E P， TEOH J G， HUNG J. Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy［J］. Curr Opin Cardiol， 2015， 30（5）： 475-482. |
| 13 | WOO A， JEDRZKIEWICZ S. The mitral valve in hypertrophic cardiomyopathy： it’s a long story［J］. Circulation， 2011， 124（1）： 9-12. |
| 14 | SCHWAMMENTHAL E， LEVINE R A. Dynamic subaortic obstruction： a disease of the mitral valve suitable for surgical repair？［J］. J Am Coll Cardiol， 1996， 28（1）： 203-206. |
| 15 | IBRAHIM M， RAO C， ASHRAFIAN H， et al. Modern management of systolic anterior motion of the mitral valve［J］. Eur J Cardiothorac Surg， 2012， 41（6）： 1260-1270. |
| 16 | HENEIN M， ARVIDSSON S， PILEBRO B， et al. Long mitral valve leaflets determine left ventricular outflow tract obstruction during exercise in hypertrophic cardiomyopathy［J］. Int J Cardiol， 2016， 212： 47-53. |
| 17 | GILMANOV D S H， BEVILACQUA S， SOLINAS M， et al. Minimally invasive septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy and intrinsic mitral valve disease［J］.Innovations （Phila）， 2015， 10（2）： 106-113. |
| 18 | VESELKA J， ANAVEKAR N S， CHARRON P. Hypertrophic obstructive cardiomyopathy［J］. Lancet， 2017， 389（10075）： 1253-1267. |
| 19 | MARON M S， ROWIN E J， WESSLER B S， et al. Enhanced American college of cardiology/American heart association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy［J］.JAMA Cardiol，2019，4（7）：644-657. |
| 20 | GERSH B J， MARON B J， BONOW R O， et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy： executive summary： a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines［J］. Circulation， 2011， 124（24）： 2761-2796. |
| 21 | OMMEN S R， MITAL S， BURKE M A， et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy： a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines［J］. Circulation， 2020， 142（25）： e558-e631. |
| 22 | SHERRID M V， SHETTY A， WINSON G， et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil［J］.Circ Heart Fail， 2013， 6（4）： 694-702. |
| 23 | SHERRID M V， BARAC I， MCKENNA W J， et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy［J］. J Am Coll Cardiol， 2005， 45（8）： 1251-1258. |
| 24 | HO C Y， DAY S M， AXELSSON A， et al. Valsartan in early-stage hypertrophic cardiomyopathy： a randomized phase 2 trial［J］. Nat Med， 2021， 27（10）： 1818-1824. |
| 25 | SPARROW A J， WATKINS H， DANIELS M J，et al. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations［J］. Am J Physiol Heart Circ Physiol， 2020， 318（3）： H715-H722. |
| 26 | HO C Y， OLIVOTTO I， JACOBY D， et al. Study design and rationale of EXPLORER-HCM： evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy［J］. Circ Heart Fail， 2020， 13（6）： e006853. |
| 27 | DESAI M Y， WOLSKI K， OWENS A， et al. Study design and rationale of VALOR-HCM： evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy［J］. Am Heart J， 2021， 239： 80-89. |
| 28 | VESELKA J， LIEBREGTS M， COOPER R， et al. Outcomes of patients with hypertrophic obstructive cardiomyopathy and pacemaker implanted after alcohol septal ablation［J］.JACC Cardiovasc Interv，2022，15（19）： 1910-1917. |
| 29 | ZHOU M Y， TA S J， HAHN R T， et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy［J］.JAMA Cardiol，2022，7（5）：529-538. |
| 30 | LAWRENZ T， KUHN H. Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy［J］. Z Kardiol， 2004， 93（6）： 493-499. |
| 31 | 蔡 迟， 王 靖， 楚建民， 等. 心内膜室间隔射频消融治疗肥厚型梗阻性心肌病的疗效分析［J］. 中国心脏起搏与心电生理杂志， 2021， 35（4）： 325-330. |
| 32 | LAWRENZ T， LAWIN D， RADKE K， et al. Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM［J］. J Cardiovasc Electrophysiol， 2021， 32（10）： 2617-2624. |
| 33 | 孟祥彬， 唐熠达. 经导管二尖瓣钳夹系统解除左心室流出道梗阻治疗肥厚型梗阻性心肌病的应用现状及前景［J］. 中国循环杂志， 2022， 37（3）： 298-301. |
| 34 | MORROW A G， LAMBREW C T， BRAUNWALD E. Idiopathic hypertrophic subaortic stenosis. ii. operative treatment and the results of pre- and postoperative hemodynamic evaluations［J］. Circulation， 1964， 30： 120-151. |
| 35 | WANG S Y， CUI H， YU Q J， et al. Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction［J］. J Thorac Cardiovasc Surg， 2016， 152（2）： 461-468. |
| 36 | MINAKATA K， DEARANI J A， NISHIMURA R A， et al. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae［J］. J Thorac Cardiovasc Surg， 2004， 127（2）： 481-489. |
| 37 | OMMEN S R， MARON B J， OLIVOTTO I， et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy［J］. J Am Coll Cardiol， 2005， 46（3）： 470-476. |
| 38 | RAFFA G M， ROMANO G， FALLETTA C， et al. Surgical management of hypertrophic obstructive cardiomyopathy： the role of mitral valve［J］. G Ital Cardiol （Rome）， 2019， 20（2）： 109-116. |
| 39 | LILLEHEI C W， LEVY M J. Transatrial exposure for correction of subaortic stenosis［J］. JAMA， 1963， 186： 8-13. |
| 40 | CASSELMAN F， VANERMEN H. Idiopathic hypertrophic subaortic stenosis can be treated endoscopically［J］. J Thorac Cardiovasc Surg， 2002， 124（6）： 1248-1249. |
| 41 | C J A K， MARC G A， SMEDIRA N G，et al. Robotic trans-mitral septal myectomy and papillary muscle reorientation for HOCM combined with or without mitral valve repair： technical aspects - How we do it［J］. J Card Surg， 2020， 35（11）： 3120-3124. |
| 42 | MA J X， LIU J， YUAN H Y， et al. Two-port thoracoscopic myectomy for hypertrophic cardiomyopathy with three-dimensional printing［J］. Ann Thorac Surg， 2021， 111（3）： e165-e168. |
| 43 | SUN D K， SCHAFF H V， NISHIMURA R A， et al. Transapical septal myectomy for hypertrophic cardiomyopathy with midventricular obstruction［J］. Ann Thorac Surg， 2021， 111（3）： 836-844. |
| 44 | ISLAM T M Q， DASGUPTA S， UDDIN M，et al. Midterm outcome of septal myectomy for hypertrophic obstructive cardiomyopathy （HOCM）： a single-center observational study［J］.Heart Surg Forum，2020，23（6）： E873-E879. |
| 45 | HONG J H， SCHAFF H V， NISHIMURA R A， et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy： implications for concomitant valve procedures［J］.J Am Coll Cardiol， 2016， 68（14）： 1497-1504. |
| 46 | KAPLE R K， MURPHY R T， DIPAOLA L M， et al. Mitral valve abnormalities in hypertrophic cardiomyopathy： echocardiographic features and surgical outcomes［J］. Ann Thorac Surg， 2008，85（5）：1527-1535. |
| 47 | HODGES K， RIVAS C G， AGUILERA J， et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center［J］. J Thorac Cardiovasc Surg， 2019， 157（6）： 2289-2299. |
| 48 | AUTHORS/TASK FORCE MEMBERS， ELLIOTT P M， ANASTASAKIS A， et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy： the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology （ESC）［J］. Eur Heart J， 2014， 35（39）： 2733-2779. |
| 49 | 唐亚捷， 宋云虎. 221例同期不处理二尖瓣的扩大心肌切除术对肥厚型梗阻性心肌病的治疗效果及远期预后分析［J］. 中国循环杂志， 2018， 33（S1）： 45-46. |
| 50 | VAN D L C， KOFFLARD M J， VAN H L A， et al. Sustained improvement after combined anterior mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy［J］.Circulation，2003，108（17）： 2088-2092. |
| 51 | KOFFLARD M J， VAN HERWERDEN L A， WALDSTEIN D J， et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy［J］. J Am Coll Cardiol， 1996， 28（1）： 197-202. |
| 52 | CARPENTIER A， ADAMS D H， FILSOUFI F. Carpentier’s reconstructive valve surgery［M］. Philadelphia： Saunders， 2010： 301-306. |
| 53 | HAGÈGE A A， BRUNEVAL P， LEVINE R A， et al. The mitral valve in hypertrophic cardiomyopathy： old versus new concepts［J］. J Cardiovasc Transl Res， 2011， 4（6）： 757-766. |
| 54 | BALARAM S K， SHERRID M V， DEROSE J J J R， et al. Beyond extended myectomy for hypertrophic cardiomyopathy： the resection-plication-release （RPR） repair［J］. Ann Thorac Surg， 2005， 80（1）： 217-223. |
| 55 | BALARAM S K， ROSS R E， SHERRID M V， et al. Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy［J］. Ann Thorac Surg， 2012， 94（6）： 1990-1997；discussion 1997-1998. |
| 56 | DELMO WALTER E M， JAVIER M F， HETZER R. Long-term outcome of simultaneous septal myectomy and anterior mitral leaflet retention plasty in hypertrophic obstructive cardiomyopathy： the Berlin experience［J］. Ann Cardiothorac Surg， 2017， 6（4）： 343-352. |
| 57 | MUTSUGA M， NARITA Y， USUI A. A floating stitch on the anterior mitral leaflet can eliminate systolic anterior motion in hypertrophic obstructive cardiomyopathy［J］. Semin Thorac Cardiovasc Surg， 2020， 32（2）： 266-268. |
| 58 | SHERRID M V， BALARAM S， KIM B， et al. The mitral valve in obstructive hypertrophic cardiomyopathy： a test in context［J］. J Am Coll Cardiol， 2016， 67（15）： 1846-1858. |
| 59 | NISHIMURA R A， SEGGEWISS H， SCHAFF H V. Hypertrophic obstructive cardiomyopathy： surgical myectomy and septal ablation［J］. Circ Res，2017，121（7）： 771-783. |
| 60 | HE S， HOPMEYER J， LEFEBVRE X P， et al. Importance of leaflet elongation in causing systolic anterior motion of the mitral valve［J］. J Heart Valve Dis， 1997， 6（2）： 149-159. |
| 61 | KLUES H G， MARON B J， DOLLAR A L， et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy［J］.Circulation，1992，85（5）： 1651-1660. |
| 62 | KLUES H G， PROSCHAN M A， DOLLAR A L，et al. Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy. Anatomic validation from mitral valve specimen［J］. Circulation， 1993， 88（2）： 548-555. |
| 63 | FERRAZZI P， SPIRITO P， IACOVONI A， et al. Transaortic chordal cutting： mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy［J］. J Am Coll Cardiol， 2015， 66（15）： 1687-1696. |
| [1] | Jinyu LI,Zhonghui LI,Aibin CHENG,Xuan BU,Jing BAI,Jianjun WANG. Improvement effect of TREM-1 inhibitory peptide LR12 on myocardial injury in septic mice and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 366-374. |
| [2] | Aimei LI,Jingfei HAN,Li DENG,Siyu CHEN. Protective effect of dexmedetomidine on myocardial injury in myocardial ischemia/reperfusion injury model rats [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 451-459. |
| [3] | Meng CAI,Yang GUO,Yingfang MA,Jinglei CUI,Jia LUO,Lili WEI,Yunhua ZHANG,Yang WANG. Therapeutic effect of prunetin on myocardial infarction model mice and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 125-134. |
| [4] | Chuwen WU,Mengling PENG,Yu FU,Shanshan ZHOU. Comparison of clinical characteristics and prognostic influence factors between patients with or without hypertrophic cardiomyopathy complicated by microvascular dysfunction [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1630-1637. |
| [5] | Xing YUE,Xuemei LI,Hanxiao ZHANG,Chuanyi ZUO,Lijuan ZHU,Jing LYU,Chengshun ZHANG,Xin CAO. Role of serum total bile acid level in development of arrhythmia in ApoE-/- mice [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 879-886. |
| [6] | Yue WANG,Ning MA,Jiajun LU,Chengyao WANG,Linyu CHEN,Yuchen REN,Jingwu LI,Hong SUN. Protective effect of novel composite hydrogels on H₂O₂-induced oxidative stress injury in cardiomyocytes [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 352-359. |
| [7] | Yuanyuan LIU,Qibo CAI,Yan QU,Xiujin YANG,Rongchun GUAN,Chanjun LIU. Association analysis on rs562556 polymorphism of PCSK9 gene and degree of coronary artery stenosis of patients with acute myocardial infarction [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1712-1718. |
| [8] | Junping WEI,Dajia FU,Qingwen MENG,Daofei LIN,Yanzai LIN. Effect of bone marrow mesenchymal stem cell-derived exosomes on myocardial fibrosis in rats induced by isoproterenol and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1348-1357. |
| [9] | Fengmei XIONG,Yuxiang CAI,Zhuo LIU,Na SUN,Yang LI. Alleviatory effect of curcumin on cardiomyocyte toxicity induced by doxorubicin by regulating SIRT3/SOD2 signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1339-1347. |
| [10] | Xing LIU,Jiali LIU,Liangui NIE,Maojun LIU,Junxiong ZHAO,Liuyang WANG,Jun YANG. Improvement effect of SO2 on myocardial fibrosis after acute myocardial ischemic injury in rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1125-1133. |
| [11] | Yintao ZHAO, Yingying YANG, Xiangqin ZHANG, Lu ZHENG, Yawei XU, Haibo YANG, Yuan LIU. Improvement effect of follistatin-like 1 on doxorubicin-induced acute myocardial injury in mice and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(3): 565-572. |
| [12] | Zhaohui WAN,Liang ZENG,Hui ZHOU. Effect of overexpression of Bax inhibitor 1 on cardiomyocyte apoptosis in rats with acute myocardial infarction and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 74-81. |
| [13] | Zhen LIU,Minglei HAN,Jiajia CUI,Yonglan HOU,Guangcui XU. Protective effect of losartan on acute myocardial infarction in rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(6): 1397-1406. |
| [14] | Ying CHENG,Jing YANG,Li RAO,Qiang XUE,Jie HU,Le FU,Qiaoyue ZHANG. Effects of hirudin combined with atorvastatin on vascular endothelium function in rats with acute myocardial infarction [J]. Journal of Jilin University(Medicine Edition), 2021, 47(1): 139-144. |
| [15] | ZHOU Yan, JIN Lianhua, LU Na, HANG Lizhi. Comparison of differentiation effects of BMSCs into cardiomyocytes induced by three culture methods in vitro [J]. Journal of Jilin University(Medicine Edition), 2020, 46(01): 66-72. |